About
Antibody Therapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Team (15)
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
4
As Collaborator
2
Total Enrollment
445
By Phase
PHASE1/PHASE2: 2PHASE1: 2PHASE2/PHASE3: 1PHASE2: 1
By Status
RECRUITING: 2COMPLETED: 2ACTIVE_NOT_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06548412Collaborator
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
PHASE1/PHASE2Recruiting
50 participants
Started: Jan 22, 2025 · Completed: May 1, 2029
NCT06150664Lead Sponsor
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
PHASE1Recruiting
55 participants
Started: Mar 19, 2024 · Completed: Apr 30, 2026
NCT05506943Lead Sponsor
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
PHASE2/PHASE3Active, not recruiting
150 participants
Started: Jan 9, 2023 · Completed: Dec 31, 2025
NCT05513742Lead Sponsor
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
PHASE2Completed
49 participants
Started: Dec 8, 2022 · Completed: May 15, 2025
NCT04492033Collaborator
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
PHASE1/PHASE2Terminated
41 participants
Started: Jun 22, 2020 · Completed: Jan 9, 2025
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...